Bristol-Myers Squibb
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
Inclusion Criteria: * Participants ≥18 years of age. * Participants who are prescribed mavacamten for obstructive hypertrophic cardiomyopathy * Provided informed consent to participate in the study Exclusion Criteria: * Previously or currently enrolled in clinical trials for any cardiac myosin inhibitors * Treated for \>7 days with mavacamten by the day of completing the baseline survey * Enrolled in any clinical trials at the time of or within the six-month period prior to the screening * Had heart attack requiring coronary artery bypass grafting within the three-month period prior to the…
As prescribed by treating physician
Arctuva estimate
Verify or correct the compensation shown for this listing.